Eduardo Diaz-rubio, MD, PhD

home / authors / eduardo-diaz-rubio-md-phd

Articles

UFT Plus or Minus Calcium Folinate for Metastatic Colorectal Cancer in Older Patients

Eduardo Diaz-rubio, MD, PhD;Javier Sastre, MD, PhD;Albert Abad, MD, PhD;Matilde Navarro, MD;Enrique Aranda, MD, PhD;Alfredo Carrato, MD, PhD;Manuel Gallén, MD;Eugenio Marcuello, MD;Julio Rifá, MD;Tomeu Massuti, MD;Andrés Cervantes, MD, PhD;Antonio Antón, MD, PhD;Carlos Fernandez-martos, MD

July 1st 1999

Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal

UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support

Miguel Martin, MD, PhD;Antonio Casado, MD;José Antonio López-Martin, MD;Alvaro Rodriguez-lescure, MD;Yago Nieto, MD;Francisco Ayala, MD;Eduardo Diaz-rubio, MD, PhD

September 2nd 1997

Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral

Neoadjuvant Therapy With Cisplatin/Fluorouracil vs Cisplatin/UFT in Locally Advanced Squamous Cell Head and Neck Cancer

J. L. González-Larriba, MD, PhD;I. Garcia Carbonero, MD;J. Sastre Valera, MD, PhD;P. Perez Segura, MD;Eduardo Diaz-rubio, MD, PhD

September 2nd 1997

This study compared the activity and toxicity of fluorouracil (5-FU)/cisplatin with the combination tegafur and uracil (UFT)/cisplatin in the neoadjuvant treatment of locally advanced-stage III or IV (M0)-head and neck

UFT Plus Oral Folinic Acid as Therapy for Metastatic Colorectal Cancer in Older Patients

Albert Abad, MD, PhD;Cristina Martín, MD;Matilde Navarro, MD;Javier Sastre, MD, PhD;Eduardo Diaz-rubio, MD, PhD;Eugenio Marcuello, MD;Enrique Aranda, MD, PhD;Manuel Gallén, MD;Carlos Fernandez-martos, MD

September 2nd 1997

The oral fluoropyrimidines have proved to be active in colorectal cancer in Japan and, recently, in the United States and Europe. Continuous oral administration simulates protracted fluorouracil (5-FU) continuous